PIK3CA and neoplasm: Thirty-five tumor samples were found to be evaluable; eight (23%) had PI3K pathway alterations (Fig. 1), including PIK3CA mutation (n = 2), PIK3CA amplification (n = 3), phosphatase and tensin homolog (PTEN) mutation (n = 2), and PTEN loss (n = 2).